Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NPS (NPSP; TSE:NX) raised $170 million in a bumped-up note deal. The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury